

EXHIBIT C

December 14, 2018

By Electronic Mail

U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993

Re: Authorization of FOIA Request

To Whom It May Concern:

On behalf of Boston Scientific Corporation, I consent to the Food and Drug Administration (FDA) releasing to Reed Smith LLP all documents that Reed Smith has requested pursuant to the Freedom of Information Act (FOIA) generally concerning (1) an interview of Steven L. Higgins, M.D., on April 13, 2010 at Scripps Memorial Hospital in La Jolla, California at or about 10:20 AM, that was conducted by Scott K. Zika, FDA Consumer Safety Office and Robert S. Sweeton, FDA Consumer Safety Office (hereafter, the "2010 Investigation"); (2) information provided by Dr. Higgins and others to FDA in the course of the 2010 Investigation and/or any additional investigation concerning purported defects, recalls of the Cognis and Teligen products, as well as their compliance with FDA rules and requirements; (3) FDA's final conclusions and determinations concerning the adequacy of information submitted to FDA by Boston Scientific in connection with Boston Scientific's U.S. launch of its Cognis and Teligen products, including the extent of FDA's knowledge about purported defects of those products that were discovered during and after the European launch of those products; and (4) FDA's final conclusions and determinations concerning the adequacy of Boston Scientific's 2009 recall of the Cognis and Teligen products; and (5) any additional documents related to the above matters, including the specific categories of documents contained in the FOIA request letter that Reed Smith previously sent to the FDA.

Very truly yours,



Daniel Gerhan
Director and Senior Litigation Counsel,
Boston Scientific Corporation